Dr. Jonathan D. Santoro
Child Neurology (Neurology with Special Qualifications in Child Neurology Physician)
725 Welch Rd
Palo Alto, CA 94304
Who else practices at this address →
Santa Clara County includes mental health (13% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Tulane University School of Medicine (2013)
- Years since graduation
- 13
- In the NPI registry since
- 2013
- Medicare patients seen, 2024
- 18
Licensed in California since 2014, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2013Medical school: Tulane University School of Medicine
- 2013Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology with Special Qualifications in Child Neurology Physician primary
CA license A131807 (first issued 2014; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Children's Hosp of Los Angeles Los Angeles, CA
Medical groups
- Childrens Hospital Los Angeles Medical Group Inc (295 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 18
- Services billed
- 50
- Patients’ average age
- 28
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Octagam (immun globg(igg)/malt/iga ov50) | 74 |
| Lorazepam Other prescribers in Palo Alto, CA | 38 |
| Panzyga (immun glob g(igg)-ifas/glycine) | 20 |
| Privigen (immun glob g(igg)/pro/iga 0-50) | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 11 payments worth $13,000 in total to this clinician.
| UCB SA | $10,280 |
|---|---|
| Amgen Inc. | $2,058 |
| Tg Therapeutics, Inc. | $336 |
| Biogen, Inc. | $214 |
| UCB, Inc. | $85.81 |
| Cycle Pharmaceuticals Inc | $25.99 |
| Consulting Fee | $12,488 |
|---|---|
| Food and Beverage | $512 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| UCB SA Mar 28, 2025 | Consulting Fee Rystiggo · Neurology | $7,000 |
| Amgen Inc. Nov 4, 2025 | Consulting Fee BLINCYTO · Oncology | $2,058 |
| UCB SA Mar 14, 2025 | Consulting Fee | $1,640 |
| UCB SA Dec 19, 2025 | Consulting Fee | $1,640 |
| Biogen, Inc. May 15, 2025 | Consulting Fee TYSABRI · Neurology | $150 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $581,178 in research payments for these studies, mostly to the institutions running them.
- A 2-year Randomized, 3-arm, Double-blind, Non-inferiority Study Comparing the Efficacy and Safety of Ofatumumab and Siponimod Versus Fingolimod in Pediatric Patients With Multiple Sclerosis Followed by an Open-label E…
Novartis Pharmaceuticals Corporation - Non-IMP clinical study to generate data on the natural history of disease, biomarkers, and relevance of clinical endpoints in patients with selected type 1 interferonopathies
Boehringer Ingelheim International GmbH - Natural History Study of Selected Type 1 Interferonopathies Based on Data of Medical Records
Boehringer Ingelheim International GmbH
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.